- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Conditions for Administering Bispecific Therapy
Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.
EP: 1.Conditions for Administering Bispecific Therapy
EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics
EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration
EP: 4.Pain Points In Bispecific Operationalization
EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
EP: 6.Optimizing Bispecific Use Through EMR Utilization
EP: 7.Best Practices For Uptake and Use of Bispecific Therapy
EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy
EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions
EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies
EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care
EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies
EP: 13.Managed Care Considerations Within Bispecific Landscape
EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies
EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy
EP: 16.Bispecific Therapies: Current and Future Considerations
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
The video discusses considerations for operationalizing bispecific monoclonal antibodies in cancer care. It highlights the importance of having protocols in place for patient monitoring, transition of care, risk evaluation and mitigation strategies programs, management of adverse events like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term toxicity monitoring. Key factors include setting patient eligibility criteria, caregiver reliability for adherence, transportation to handle severe adverse effects, and financial considerations for insurance authorizations. As these are continuous therapies, extensive plans must be made to support patients across the entirety of their treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
